Ann: Selected for oral presentation at ASH, page-9

Less than 4 weeks ( Dec 9th US time) until the long awaited and company making interim results from its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib to treat the bone marrowcancer myelofibrosis, will be presented.

I discussed with Gary with what happens if the results are at hand before the presentation. Surely there is an ASX reporting obligation that these results are made known to shareholders before Dec 9th ASH presentation. He stated the conference wants the results to be announced first at the conference. Quite a quandary. Maybe we will go into a trading halt for a couple of days prior.

These results are a big company valuation inflection point and the market is not yet pricing any positive news imo and given the value in SNT's other indications there doesn't appear to be much downside.